Every issue, newest first. The archive builds forward from issue one and is never backfilled.
The week's two strongest results are a pivotal oral angioedema trial and a Parkinson's trial in which a supplement did worse than placebo
Six of the ten are incretin trials from the diabetes congress week, led by a dual agonist whose full results were new to everyone at once
The strongest trials this week made the case for doing less, from fewer colonoscopies to two fewer cycles of chemotherapy
Most of this week's ranked papers documented results that had already been public for months
Three device trials returned null results in one week and the strongest positive readings came from a sham comparison that failed